The combined global market size of medical conditions we target exceeds US$400B per annum. This potential addressable market is calculated by combining the treatment markets of OSA, TBI, concussion, rheumatoid arthritis, inflammatory bowel disease, inflammatory lung conditions (ARDS, COPD, Asthma, Bronchitis) and generalised anxiety disorder (GAD). Success in the clinical development programmes will not only provide benefit to patients, but also offer significant economic potential for our shareholders.
Introducing The Clarion Clinics Group
Psychennex is pioneering the worldʼs leading Psychedelic-Assisted Psychotherapy Clinics.
Introducing The Clarion Clinics Group
Psychennex is pioneering the worldʼs leading Psychedelic-Assisted Psychotherapy Clinics.
The Potential is Limitless
Incannex is a global leader in the development of novel, medicinal cannabinoid compounds and psychedelic therapies.
The Potential is Limitless
Incannex is a global leader in the development of novel, medicinal cannabinoid compounds and psychedelic therapies.
Boundless Medical Developments
Undertaking 28 clinical programs, targeting conditions for which there are no current pharmacotherapy treatments.
Boundless Medical Developments
Undertaking 28 clinical programs, targeting conditions for which there are no current pharmacotherapy treatments.
Unrivalled Economic Opportunities
The addressable global market size of the indications we are targeting is over US$400 billion.
Unrivalled Economic Opportunities
The addressable global market size of the indications we are targeting is over US$400 billion.
Our mission is to alleviate human suffering by creating novel, ethical drugs and therapies for patients with unmet medical needs, utilising compounds and delivery systems with strong pre-existing scientific signals of efficacy.
28 R&D programs and 6 clinical trials, with 1 primary goal – alleviate human suffering.
Clinical Development Pathway
Incannex is a medicinal cannabinoid and psychedelic therapy development company undertaking phase 2 clinical trials guided by its extended team, post liaison with FDA. With a diverse portfolio of 28 distinct research and development programs, 6 clinical trials underway and more planned, our programs target conditions for patients with unmet medical needs. This means we have an opportunity to treat a significant number of people – the potential is limitless.
US$400B market potential.
Latest results and presentations
Joel Latham’s Quest to Transform Modern Medicine
Health & Biotech Frontiers of Healing: Joel Latham’s Quest to Transform Modern Medicine...Psi-GAD1 Positive Topline Results from Phase 2 Clinical Trial
Health & Biotech Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised...Phase 2 “PsiGAD” Clinical Trial Dosing and Therapy Complete
Health & Biotech Incannex Completes Dosing and Therapy in Phase 2 "PsiGAD" Clinical Trial Assessing Psilocybin-assisted Psychotherapy for...Clarion Clinics receives ethical endorsement
Health & Biotech How Melbourne psychedelic treatment clinic 'Clarion Clinics' on Yarra River front will work. Australia’s first...Top 20 Shareholder Report October 2023
Health & Biotech Top 20 shareholder report as of October 16, 2023....FDA application prepared: Psilocybin-assisted psychotherapy program
Health & Biotech Incannex Healthcare (ASX: IHL) subsidiary Psychennex Pty Ltd has started preparing an investigational new drug (IND)...FDA clearance to start IHL-42X clinical trial with OSA patients
Health & Biotech Incannex Healthcare (ASX: IHL) has received approval from the US Food and Drug Administration (FDA) to...Clarion Clinics ready to open
Health & Biotech Incannex Healthcare’s (ASX: IHL) subsidiary, Clarion Clinics Group, has begun accepting registrations of interest from...Positive pre-IND meeting for IHL-675A arthritis treatment
Health & Biotech Chief scientific officer Dr Mark Bleackley tells Proactive about its positive pre-IND meeting for IHL-675A...Key application submitted to FDA for $15bn sleep apnoea market
Health & Biotech Key application submitted to FDA for new treatment in $15 billion sleep apnoea market...Ethics approval: Phase 2 clinical trial – rheumatoid arthritis
Health & Biotech Incannex has been given the green light to start its Phase 2 clinical trial to...Subscribe
Stay up to date with Incannex’s research and development program.